2021
DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo
Tymon-Rosario J, Bonazzoli E, Bellone S, Manzano A, Pelligra S, Guglielmi A, Gnutti B, Nagarkatti N, Zeybek B, Manara P, Zammataro L, Harold J, Mauricio D, Buza N, Hui P, Altwerger G, Menderes G, Ratner E, Clark M, Andikyan V, Huang GS, Silasi DA, Azodi M, Schwartz PE, Santin AD. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo. Gynecologic Oncology 2021, 163: 334-341. PMID: 34452746, PMCID: PMC8722447, DOI: 10.1016/j.ygyno.2021.08.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedBenzodiazepinesBystander EffectCell Line, TumorCystadenocarcinoma, SerousDrug Resistance, NeoplasmFemaleHumansImmunoconjugatesMiddle AgedPrimary Cell CultureReceptor, ErbB-2TrastuzumabUterine NeoplasmsXenograft Model Antitumor AssaysConceptsHER2/neuPrimary USC cell linesUSC cell linesUterine serous carcinomaSerous carcinomaHER2/Cell linesBystander killingHER2/neu protein expressionHER2/neu overexpressionProtein expressionNovel treatment optionsAggressive histologic variantNeu protein expressionHER2 protein expressionC-erbB2 gene amplificationSignificant bystander killingUSC xenograftsEndometrial cancerNegative tumorsPoor prognosisPositive tumorsTreatment optionsPreclinical activityHistologic variants
2011
Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus
Shahabi S, Pellicciotta I, Hou J, Graceffa S, Huang GS, Samuelson RN, Goldberg GL. Clinical utility of chromogranin A and octerotide in large cell neuro endocrine carcinoma of the uterine corpus. Rare Tumors 2011, 3: 41. PMID: 22355496, PMCID: PMC3282446, DOI: 10.4081/rt.2011.e41.Peer-Reviewed Original ResearchLarge cell neuroendocrine carcinomaNeuroendocrine tumorsUterine corpusGenital tractLarge cell neuro endocrine carcinomaLarge cell neuroendocrine tumorNeuro-endocrine carcinomaPrimary neuroendocrine tumorCell neuroendocrine carcinomaFemale genital tractPotential future therapeuticsEndocrine carcinomaAggressive treatmentInitial diagnosisUterine cervixNeuroendocrine carcinomaTreatment optionsRare caseClinical utilityChromogranin AOptimal managementTumorsFuture therapeuticsCervixCarcinoma